Fady Ibraham Malik Cytokinetics Inc (CYTK) insider trading activity

Fady Ibraham Malik is EVP Research & Development of CYTOKINETICS INC. Currently has a direct ownership of 140,255 shares of CYTK, which is worth approximately $6.06 Million. The most recent transaction as insider was on Nov 12, 2024, when has been sold 6,342 shares (Common Stock) at a price of $58.48 per share, resulting in proceeds of $370,880. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 140K

20.84% 3M change

1.33% 12M change

Total Value Held $6.06 Million

Fady Ibraham Malik Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Nov 12 2024	SELL Open market or private sale	$370,880 $58.48 p/Share	6,342 Reduced 5.28%	113,878 Common Stock
Nov 12 2024	BUY Exercise of conversion of derivative security	$42,188 $7.96 p/Share	5,300 Added 4.22%	120,220 Common Stock
Oct 30 2024	SELL Open market or private sale	$379,016 $51.92 p/Share	7,300 Reduced 5.97%	114,920 Common Stock
Oct 30 2024	BUY Exercise of conversion of derivative security	$42,188 $7.96 p/Share	5,300 Added 4.16%	122,220 Common Stock
Oct 15 2024	SELL Open market or private sale	$395,587 $54.19 p/Share	7,300 Reduced 5.88%	116,920 Common Stock
Oct 15 2024	BUY Exercise of conversion of derivative security	$42,188 $7.96 p/Share	5,300 Added 4.09%	124,220 Common Stock
Oct 01 2024	SELL Open market or private sale	$380,330 $52.1 p/Share	7,300 Reduced 5.78%	118,920 Common Stock
Oct 01 2024	BUY Exercise of conversion of derivative security	$42,188 $7.96 p/Share	5,300 Added 4.09%	124,220 Common Stock
Sep 17 2024	SELL Open market or private sale	$414,348 $56.76 p/Share	7,300 Reduced 5.69%	120,920 Common Stock
Sep 17 2024	BUY Exercise of conversion of derivative security	$42,188 $7.96 p/Share	5,300 Added 3.97%	128,220 Common Stock
Sep 03 2024	SELL Open market or private sale	$420,961 $57.01 p/Share	7,384 Reduced 5.67%	122,920 Common Stock
Sep 03 2024	BUY Exercise of conversion of derivative security	$42,188 $7.96 p/Share	5,300 Added 3.97%	128,220 Common Stock
Aug 20 2024	SELL Open market or private sale	$410,552 $56.24 p/Share	7,300 Reduced 5.52%	125,004 Common Stock
Aug 20 2024	BUY Exercise of conversion of derivative security	$42,188 $7.96 p/Share	5,300 Added 3.91%	130,304 Common Stock
Aug 07 2024	BUY Exercise of conversion of derivative security	$42,188 $7.96 p/Share	5,300 Added 4.01%	127,004 Common Stock
Aug 06 2024	SELL Open market or private sale	$392,156 $53.72 p/Share	7,300 Reduced 5.57%	123,704 Common Stock
Jul 23 2024	SELL Open market or private sale	$416,246 $57.02 p/Share	7,300 Reduced 5.36%	129,004 Common Stock
Jul 23 2024	BUY Exercise of conversion of derivative security	$42,188 $7.96 p/Share	5,300 Added 3.8%	134,304 Common Stock
Jul 09 2024	SELL Open market or private sale	$408,070 $55.9 p/Share	7,300 Reduced 5.28%	131,004 Common Stock
Jul 09 2024	BUY Exercise of conversion of derivative security	$42,188 $7.96 p/Share	5,300 Added 3.69%	138,304 Common Stock
Jun 25 2024	SELL Open market or private sale	$392,229 $53.73 p/Share	7,300 Reduced 5.2%	133,004 Common Stock
Jun 25 2024	BUY Exercise of conversion of derivative security	$42,188 $7.96 p/Share	5,300 Added 3.69%	138,304 Common Stock
Jun 11 2024	SELL Open market or private sale	$413,075 $53.04 p/Share	7,788 Reduced 5.45%	135,004 Common Stock
Jun 11 2024	BUY Exercise of conversion of derivative security	$43,159 $7.96 p/Share	5,422 Added 3.66%	142,792 Common Stock
May 07 2024	SELL Open market or private sale	$1,012,265 $65.11 p/Share	15,547 Reduced 10.19%	137,056 Common Stock

Also insider at

RCKT

ROCKET PHARMACEUTICALS, INC. Healthcare

FIM